Full dose–response curves, based on the hexadecyltrimethylammonium bromide (HDTA)-stable mouse tau pathology, showed that ADT40P1 activity reaches the same plateau as AD-tau in the neuronal assay (Fig. 2d), indicating that the pathogenic tau species in ADT40P1 is equally potent to AD-tau. Here, MAPT is linked to Alzheimer disease.